TNFRSF18 Antikörper

Produktnummer ABIN2664611

Produktdetails anti-TNFRSF18 Antikörper

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFRSF18 Antikörper ist unkonjugiert

Applikation: Immunofluorescence (IF), Intracellular Flow Cytometry (ICFC)

Aufreinigung: The antibody was purified by affinity chromatography.

Klon: 621

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TNFRSF18

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Andere Bezeichnung: CD357 (TNFRSF18 Produkte)

Synonyme: GITR antikoerper, TNFRSF18 antikoerper, AITR antikoerper, Gitr antikoerper, CD357 antikoerper, GITR-D antikoerper, TNF receptor superfamily member 18 antikoerper, tumor necrosis factor receptor superfamily, member 18 antikoerper, TNFRSF18 antikoerper, Tnfrsf18 antikoerper

Hintergrund: GITR (glucocorticoid-induced TNF receptor family-regulated gene) is a 25 kD TNF receptor superfamily member (also known as AITR and TNFRSF18). GITR is expressed on activated lymphocytes and is upregulated by T cell receptor engagement. The cytoplasmic domain of GITR is homologous to CD40, 4-1BB and CD27 and has been shown to interact with TRAF 1-3, but not TRAF 5 or 6. GITR signaling has been shown to regulate T cell proliferation and TCR-mediated apoptosis, and to break immunological self-tolerance. GITR binds GITRL and is involved in the development of regulatory T cells and to regulate the activity of Th1 subsets.

Pathways: Cancer Immune Checkpoints